Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/3121
Title: | Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals | Authors: | Mirjana Bećarević | Keywords: | Antibodies against complement components;Antiphospholipid antibodies;Biomarkers;Biopharmaceuticals;Complement | Issue Date: | 1-Jul-2017 | Journal: | Current Rheumatology Reports | Abstract: | © 2017, Springer Science+Business Media New York. Purpose of Review: Laboratory criterion for the diagnosis of antiphospholipid syndrome (APS) is the presence of antiphospholipid antibodies (aPL Abs). Complement system has a role in mediating aPL Abs-induced thrombosis in animal models. The importance of antibodies against complement components (potential biomarkers of APS) and the importance of antibodies with beneficial anti-complement effects in APS (as biopharmaceuticals) are reviewed. Recent Findings: Antibodies against complement components described in APS patients, so far, are anti-C1q and anti-factor H Abs, although anti-factor B Abs and anti-C5a Abs were described in animal models of APS. Clinical studies in APS patients are limited to a small number of case reports. Summary: Studies that would confirm potential role of Abs against complement components (as potential biomarkers of APS) are lacking. Lack of randomized clinical trials (that would provide complete data for confirmation of beneficial effects of biopharmaceuticals in complement inhibition) in APS is alarming. | URI: | https://open.uns.ac.rs/handle/123456789/3121 | ISSN: | 15233774 | DOI: | 10.1007/s11926-017-0669-1 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
6
checked on May 10, 2024
Page view(s)
35
Last Week
8
8
Last month
6
6
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.